Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSPECTIVE: LCZ696 vs Valsartan on Cognitive Function in HFpEF
NCT02884206Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2016
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF), sponsored by Novartis. Started Nov 2016; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT02884206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02884206.